Beth Hoffman

Beth Hoffman

Company: Origami Therapeutics

Job title: Founder, President & CEO


Use of High Content Screening to Identify Conformation Modulators as Therapeutics for Huntington’s Disease 10:30 am

• Phenotypic assays enabled identification of small molecules that prevent disease-causing mutated huntingtin aggregation • Deconvolution of phenotypic screening to determine mechanism of action • The use of chemo-phenomics and patient-derived model systems to select and optimize leads with therapeutic potentialRead more

day: Day Two

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.